tiprankstipranks
Trending News
More News >
Croda International PLC (GB:CRDA)
LSE:CRDA
Advertisement

Croda International (CRDA) AI Stock Analysis

Compare
142 Followers

Top Page

GB:CRDA

Croda International

(LSE:CRDA)

Rating:62Neutral
Price Target:
2,754.00p
▲(8.04%Upside)
Croda International's overall stock score is driven by stable financial health and positive insider confidence, offset by bearish technical indicators and premium valuation. The company's strategic cost-saving measures and strong sales growth provide a positive outlook despite current challenges.

Croda International (CRDA) vs. iShares MSCI United Kingdom ETF (EWC)

Croda International Business Overview & Revenue Model

Company DescriptionCroda International Plc creates, makes, and sells specialty chemicals in Europe, the Middle East, Africa, North America, Asia, and Latin America. It operates through four segments: Consumer Care, Life Sciences, Performance Technologies, and Industrial Chemicals. The company offers adhesives; crop protection additives and adjuvants, seed enhancement and animal health chemicals, chemical bio-stimulants, and specialty additives for agricultural films; and lubricant additives, coatings and polymers, vehicle cleaning chemicals, and products for automotive textiles and fibers, as well as specialty additives for plastics, and battery and catalyst industries. It also provides specialty ingredients for self-tanning, color cosmetics, bath and shower, deodorants, anti-perspirants, depilatories, men's grooming, and oral hygiene, as well as skin, hair, sun, body, and baby care applications; construction chemicals and bitumen additives; dietary supplements; and materials and polymer additives for electronics and devices. In addition, the company offers chemistries, emulsifiers, fuel and power generation additives, and polymer additives; food additives; specialty polymer additives for furniture and wood applications; household, industrial, and institutional cleaning products; lubricants; oleochemicals; and packaging, print, and paper chemicals. Further, it provides paints and coatings; active pharmaceutical ingredients; thermal management products; plastic and rubber products; skin health products; hygiene and industrial nonwovens, botanical extracts, tissues, and textile auxiliaries; and water treatment chemicals. Additionally, the company offers bio-based phase change materials for buildings and ventilation, clothing and healthcare, electronics and devices, food and refrigeration, energy storage and recovery, temperature controlled packaging, and vehicles and automotive applications. The company was incorporated in 1925 and is headquartered in Goole, the United Kingdom.
How the Company Makes MoneyCroda International makes money primarily by manufacturing and selling specialty chemical ingredients to a diverse range of industries. Its revenue streams are driven by its four main segments: Personal Care, Life Sciences, Performance Technologies, and Industrial Chemicals. The Personal Care segment provides ingredients for skin and hair care products, while the Life Sciences segment focuses on healthcare and crop care, supplying ingredients for pharmaceuticals and agricultural products. The Performance Technologies segment offers solutions for automotive, polymer, and lubricant markets, and the Industrial Chemicals segment provides various raw materials used in different industrial applications. Croda's strategy involves significant investment in research and development to create innovative and sustainable products, often in collaboration with major global companies, which enhances its competitive position and drives its earnings.

Croda International Earnings Call Summary

Earnings Call Date:Jul 29, 2025
(Q2-2025)
|
% Change Since: -12.07%|
Next Earnings Date:Feb 24, 2026
Earnings Call Sentiment Positive
The earnings call presented a positive outlook with strong sales and profit growth across multiple segments, supported by substantial cost savings initiatives. However, there are challenges due to political uncertainties in the US and exceptional charges that impacted profitability.
Q2-2025 Updates
Positive Updates
Group Sales Increase
Group sales increased by 7% for the first half of the fiscal year, with growth across all three business segments and regions.
Adjusted Operating Profit Growth
Adjusted operating profit increased by 12% to GBP 147 million, and adjusted profit before tax also grew by 12% to GBP 138 million.
Volume Growth
Volumes were up 11%, driven by strong growth in each business segment, with Consumer Care volumes increasing by 9% and Agriculture by 13%.
Cost Savings Plan
An additional GBP 60 million in cost savings was identified, bringing the total to GBP 100 million of annualized savings by the end of 2027.
Strong Operating Margin in Life Sciences
Life Sciences adjusted operating profit increased by 30% to GBP 56 million, with an operating margin improvement from 18.3% to 21.5%.
Consumer Health Sales Growth
Consumer Health sales grew 10%, with three consecutive quarters of steady progress.
Negative Updates
Exceptional Charges and Impairments
Reported profit before tax of GBP 85.5 million includes a GBP 7 million exceptional restructuring charge, GBP 18 million for amortization of acquired intangibles, and a GBP 27 million impairment charge.
US Market Challenges
Political uncertainty and policy decisions in the USA negatively impacted consumer confidence and slowed approval processes, affecting Beauty Actives and Pharma sales.
Lower Price/Mix
Price/mix was 4% lower as the company selectively reduced prices to regain share at the bottom end of the Agriculture and Beauty Care portfolios.
High Inventory Levels
Higher than expected inventory levels led to a free cash flow of GBP 34 million and net debt of GBP 580 million.
Company Guidance
During the call, the company provided guidance that despite a challenging political and economic environment, their full-year outlook remains unchanged. They expect adjusted profit before tax to be between GBP 265 million and GBP 295 million in constant currency. For the first half, group sales increased by 7%, with volumes up 11% and adjusted operating profit growing by 12% to GBP 147 million. The company also aims to achieve GBP 100 million in annualized cost savings by the end of 2027, doubling the original target, with GBP 25 million expected to be realized in the current year. Additionally, the company reported a free cash flow of GBP 34 million and a net debt of GBP 580 million, maintaining a conservative leverage ratio of 1.5x EBITDA. They declared an interim dividend of 48p, reflecting a slight increase from the previous year.

Croda International Financial Statement Overview

Summary
Croda International's financial performance shows solid financial health with strong equity and cost management. However, challenges arise from declining revenue and profitability margins. Stable cash flow generation suggests resilience, but growth pressures exist.
Income Statement
65
Positive
Croda International's income statement shows a contraction in total revenue from 2022 to 2024, with a negative trend in revenue growth rate. The gross profit margin remains strong at approximately 45%, indicating efficient cost management. However, the net profit margin has decreased, reflecting declining profitability. The EBIT and EBITDA margins are also decreasing, signaling weakening operating performance.
Balance Sheet
72
Positive
The balance sheet is relatively stable with a moderate debt-to-equity ratio. The company's equity ratio is robust, indicating a solid equity base. Despite a slight increase in debt over the years, there’s a consistent stockholders' equity, suggesting financial stability. However, the return on equity has been declining, which may affect investor confidence.
Cash Flow
68
Positive
The cash flow statements indicate stable operating cash flow, though free cash flow has shown minor fluctuations. The free cash flow to net income ratio is healthy, suggesting efficient cash conversion. Despite a decrease in free cash flow in the latest year, the operating cash flow to net income ratio remains strong, highlighting stable cash generation capacity.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.63B1.69B2.09B1.89B1.39B
Gross Profit733.90M730.00M864.90M825.60M550.30M
EBITDA374.50M388.50M924.80M549.40M369.60M
Net Income158.50M171.00M649.30M320.80M201.60M
Balance Sheet
Total Assets3.51B3.58B3.61B3.29B3.03B
Cash, Cash Equivalents and Short-Term Investments166.80M172.50M320.60M112.80M106.50M
Total Debt699.10M710.10M615.80M936.00M907.00M
Total Liabilities1.21B1.21B1.18B1.53B1.43B
Stockholders Equity2.28B2.35B2.42B1.75B1.59B
Cash Flow
Free Cash Flow137.60M156.80M160.90M190.50M166.30M
Operating Cash Flow319.40M337.50M313.30M349.20M287.50M
Investing Cash Flow-139.10M-409.80M418.10M-218.40M-992.40M
Financing Cash Flow-182.60M-52.40M-550.90M-111.90M722.40M

Croda International Technical Analysis

Technical Analysis Sentiment
Negative
Last Price2549.00
Price Trends
50DMA
2984.20
Negative
100DMA
2951.25
Negative
200DMA
3140.04
Negative
Market Momentum
MACD
-79.65
Positive
RSI
25.17
Positive
STOCH
23.40
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:CRDA, the sentiment is Negative. The current price of 2549 is below the 20-day moving average (MA) of 2894.15, below the 50-day MA of 2984.20, and below the 200-day MA of 3140.04, indicating a bearish trend. The MACD of -79.65 indicates Positive momentum. The RSI at 25.17 is Positive, neither overbought nor oversold. The STOCH value of 23.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:CRDA.

Croda International Peers Comparison

Overall Rating
UnderperformOutperform
Sector (62)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
72
Outperform
£2.99B8.4215.96%4.31%-9.10%239.75%
66
Neutral
£608.83M20.506.65%8.51%4.75%-3.29%
64
Neutral
£121.45M11.178.02%4.08%1.12%-0.70%
62
Neutral
$10.39B9.841.51%2.86%2.35%-34.25%
62
Neutral
£4.05B28.936.17%3.21%2.36%-13.99%
59
Neutral
£941.13M-5.93%1.05%0.71%-274.39%
52
Neutral
£147.69M-6.25%0.81%15.63%
* Basic Materials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GB:CRDA
Croda International
2,549.00
-1,277.22
-33.38%
GB:ELM
Elementis
160.80
5.36
3.45%
GB:JMAT
Johnson Matthey
1,770.00
242.24
15.86%
GB:SYNT
Synthomer
84.40
-173.10
-67.22%
GB:TET
Treatt plc
201.00
-240.26
-54.45%
GB:VCT
Victrex
689.00
-333.93
-32.64%

Croda International Corporate Events

Other
Croda CFO Purchases Shares, Signaling Confidence
Positive
Jul 29, 2025

Croda International Plc announced a transaction involving its Chief Financial Officer, Stephen Richard Oxley, who purchased 3,762 ordinary shares at a price of £26.71 each, totaling £100,483.02. This transaction, disclosed as an initial notification, reflects the company’s ongoing commitment to transparency and may indicate confidence in the company’s future performance, potentially impacting investor sentiment positively.

The most recent analyst rating on (GB:CRDA) stock is a Buy with a £46.00 price target. To see the full list of analyst forecasts on Croda International stock, see the GB:CRDA Stock Forecast page.

Other
Croda Executive Purchases Shares, Signaling Confidence
Positive
Jul 29, 2025

Croda International Plc announced a transaction involving Thomas Herman Riermeier, a member of its Executive Committee, who purchased 1,000 ordinary shares at a price of £26.959 each. This transaction, conducted on July 29, 2025, at the London Stock Exchange, reflects insider confidence in the company’s prospects and could influence stakeholder perceptions positively.

The most recent analyst rating on (GB:CRDA) stock is a Buy with a £46.00 price target. To see the full list of analyst forecasts on Croda International stock, see the GB:CRDA Stock Forecast page.

Business Operations and StrategyFinancial Disclosures
Croda International Reports Strong First Half Sales Growth Amid Strategic Efficiency Drive
Positive
Jul 29, 2025

Croda International Plc reported a 7% increase in group sales at constant currency for the first half of 2025, driven by higher sales volumes across all its business sectors. Despite a challenging economic environment, the company maintained its full-year outlook and identified additional cost savings, aiming for £100 million in annualized savings by 2027. The strategic focus on operational efficiency and innovation is expected to strengthen Croda’s market position and improve returns, with adjusted operating profit up by 12% at constant currency.

The most recent analyst rating on (GB:CRDA) stock is a Buy with a £46.00 price target. To see the full list of analyst forecasts on Croda International stock, see the GB:CRDA Stock Forecast page.

Business Operations and StrategyFinancial Disclosures
Croda International Reports Strong H1 2025 Sales Growth Amid Strategic Efficiency Drive
Positive
Jul 29, 2025

Croda International reported a 7% sales growth at constant currency for the first half of 2025, driven by increased volumes across all business sectors, particularly in Beauty Care and Crop Protection. Despite a challenging environment, the company is on track with its strategic plan to enhance earnings and returns, with a focus on cost savings and operational efficiency, aiming for £100m in annualized savings by 2027.

The most recent analyst rating on (GB:CRDA) stock is a Buy with a £46.00 price target. To see the full list of analyst forecasts on Croda International stock, see the GB:CRDA Stock Forecast page.

Executive/Board ChangesBusiness Operations and Strategy
Croda International Announces PDMR Share Transactions
Neutral
Jul 16, 2025

Croda International Plc has announced a notification regarding transactions by persons discharging managerial responsibilities (PDMRs) and their closely associated persons. The announcement details the purchase of shares under the Company’s Share Incentive Plan, with shares being purchased and awarded to various executives and committee members. This move is part of Croda’s ongoing efforts to align the interests of its management with those of its shareholders, potentially impacting the company’s market positioning by reinforcing stakeholder confidence.

The most recent analyst rating on (GB:CRDA) stock is a Buy with a £46.00 price target. To see the full list of analyst forecasts on Croda International stock, see the GB:CRDA Stock Forecast page.

Business Operations and Strategy
Croda International Announces Share Transactions for Executives
Neutral
Jun 12, 2025

Croda International Plc announced a series of share transactions involving key managerial personnel as part of its Share Incentive Plan. The transactions, conducted on June 10, 2025, involved the purchase of partnership shares, matching shares, and dividend reinvestment shares for several executives, reflecting the company’s ongoing commitment to aligning management interests with shareholder value.

The most recent analyst rating on (GB:CRDA) stock is a Buy with a £46.00 price target. To see the full list of analyst forecasts on Croda International stock, see the GB:CRDA Stock Forecast page.

Regulatory Filings and Compliance
Croda International Discloses Managerial Share Transactions
Neutral
Jun 2, 2025

Croda International Plc has announced a notification regarding transactions by individuals with managerial responsibilities within the company. The transactions involved the purchase of ordinary shares by Thomas Michael Brophy, the Company Secretary, and Sarah Elizabeth Brophy, a person closely associated with him. The purchases were conducted on May 29, 2025, at a price of £30.697651 per share, with varying volumes. This disclosure highlights transparency in the company’s operations and adherence to regulatory requirements, potentially impacting stakeholder confidence.

The most recent analyst rating on (GB:CRDA) stock is a Buy with a £46.00 price target. To see the full list of analyst forecasts on Croda International stock, see the GB:CRDA Stock Forecast page.

DividendsRegulatory Filings and Compliance
Croda International Announces Executive Share Transaction
Neutral
May 29, 2025

Croda International Plc announced a transaction involving Mrs. Sandra Elaine Breene, a member of its Executive Committee. The transaction involved the reinvestment of dividends into ordinary shares, with a total aggregated volume of 5 shares at a price of £154.00. This notification highlights the company’s ongoing efforts to maintain transparency in its financial dealings and may impact stakeholder perceptions regarding executive management’s commitment to the company’s growth.

The most recent analyst rating on (GB:CRDA) stock is a Buy with a £46.00 price target. To see the full list of analyst forecasts on Croda International stock, see the GB:CRDA Stock Forecast page.

Business Operations and Strategy
Croda International Aligns Management Interests with Shareholder Value
Neutral
May 13, 2025

Croda International Plc has announced the purchase of shares under the Company’s Share Incentive Plan by the SIP Trustee, MUFG Corporate Markets Trustees (Nominees) Ltd. The transaction involves the acquisition of partnership shares and the awarding of matching shares to persons discharging managerial responsibilities (PDMRs) within the company, reflecting a strategic move to align management interests with shareholder value.

The most recent analyst rating on (GB:CRDA) stock is a Buy with a £46.00 price target. To see the full list of analyst forecasts on Croda International stock, see the GB:CRDA Stock Forecast page.

Other
Croda International Director Purchases Shares, Signaling Confidence
Positive
May 6, 2025

Croda International Plc announced a transaction involving the purchase of 1,000 ordinary shares by Ian Alan Bull, a Non-Executive Director. This transaction, conducted on May 6, 2025, at the London Stock Exchange, reflects a financial commitment to the company, potentially signaling confidence in its market position and future prospects.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 30, 2025